{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:amin-pharmaceutical-company",
    "identifier": "hg:company:amin-pharmaceutical-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Amin Pharmaceutical Company",
    "slug": "amin-pharmaceutical-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/amin-pharmaceutical-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/amin-pharmaceutical-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/amin-pharmaceutical-company",
    "summary": "",
    "machine_summary": "Amin Pharmaceutical Company Amin Pharmaceutical Company is a listed pharmaceutical manufacturer headquartered in Isfahan Province. In the Hormuz Group company graph, it matters because it links central Iran's manufacturing base with medicine production, pharmacy distribution, therapeutic staples, regulatory pricing, and imported pharmaceutical inputs. Its listed status makes it useful for monitoring pharmaceutical disclosure, margins, working capital, raw-material exposure, and demand stability in regulated healthcare categories. Amin Pharmaceutical is relevant for investors assessing Iran's listed drug-manufacturing sector, domestic healthcare demand, pharmaceutical import substitution, and the operating economics of medicine producers outside Tehran. It can support analysis of raw-material procurement, distributor receivables, product registration, pricing policy, and resilience during medicine shortages. Due diligence should review updated financial statements, product mix, API sourcing, GMP compliance, export channels, ownership, working capital, and exposure to currency or reimbursement delays. Amin Pharmaceutical Company manufactures pharmaceutical preparations, including solid, semi-solid, and liquid dosage forms for common therapeutic categories. Its operations support pharmacy supply, hospital demand, domestic drug manufacturing, contract or licensed production, raw-material import substitution, and healthcare-sector distribution from its Isfahan-based industrial platform. province: Isfahan industry: Healthcare & Pharma, Manufacturing, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer city: Isfahan",
    "published_at": "2026-06-28T20:21:36+00:00",
    "modified_at": "2026-06-28T20:21:36+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 4,
                "name": "Isfahan",
                "slug": "isfahan",
                "url": "https://hormuz.group/provinces/isfahan/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 16,
                "name": "Manufacturing",
                "slug": "manufacturing",
                "url": "https://hormuz.group/industry/manufacturing/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            }
        ],
        "city": [
            {
                "id": 352,
                "name": "Isfahan",
                "slug": "isfahan",
                "url": "https://hormuz.group/cities/isfahan/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Isfahan",
        "industry": "Healthcare & Pharma, Manufacturing, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer",
        "city": "Isfahan"
    },
    "fields_summary": {
        "legal_name": "Amin Pharmaceutical Company Public Joint Stock Company",
        "website": "https://www.aminpharma.com",
        "city": "Isfahan, Isfahan Province, Iran",
        "ticker_symbol": "دامین",
        "listing_status": "listed_tse",
        "products_services": "Amin Pharmaceutical Company manufactures pharmaceutical preparations, including solid, semi-solid, and liquid dosage forms for common therapeutic categories. Its operations support pharmacy supply, hospital demand, domestic drug manufacturing, contract or licensed production, raw-material import substitution, and healthcare-sector distribution from its Isfahan-based industrial platform.",
        "export_relevance": "low",
        "short_profile": "Amin Pharmaceutical Company is a listed pharmaceutical manufacturer headquartered in Isfahan Province. In the Hormuz Group company graph, it matters because it links central Iran's manufacturing base with medicine production, pharmacy distribution, therapeutic staples, regulatory pricing, and imported pharmaceutical inputs. Its listed status makes it useful for monitoring pharmaceutical disclosure, margins, working capital, raw-material exposure, and demand stability in regulated healthcare categories.",
        "investment_relevance": "Amin Pharmaceutical is relevant for investors assessing Iran's listed drug-manufacturing sector, domestic healthcare demand, pharmaceutical import substitution, and the operating economics of medicine producers outside Tehran. It can support analysis of raw-material procurement, distributor receivables, product registration, pricing policy, and resilience during medicine shortages. Due diligence should review updated financial statements, product mix, API sourcing, GMP compliance, export channels, ownership, working capital, and exposure to currency or reimbursement delays."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Amin Pharmaceutical Company Public Joint Stock Company",
        "city": "Isfahan, Isfahan Province, Iran",
        "ticker_symbol": "دامین",
        "export_relevance": "low",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_tse",
        "last_updated": "28/06/2026",
        "website": "https://www.aminpharma.com",
        "products_services": "Amin Pharmaceutical Company manufactures pharmaceutical preparations, including solid, semi-solid, and liquid dosage forms for common therapeutic categories. Its operations support pharmacy supply, hospital demand, domestic drug manufacturing, contract or licensed production, raw-material import substitution, and healthcare-sector distribution from its Isfahan-based industrial platform.",
        "short_profile": "Amin Pharmaceutical Company is a listed pharmaceutical manufacturer headquartered in Isfahan Province. In the Hormuz Group company graph, it matters because it links central Iran's manufacturing base with medicine production, pharmacy distribution, therapeutic staples, regulatory pricing, and imported pharmaceutical inputs. Its listed status makes it useful for monitoring pharmaceutical disclosure, margins, working capital, raw-material exposure, and demand stability in regulated healthcare categories.",
        "investment_relevance": "Amin Pharmaceutical is relevant for investors assessing Iran's listed drug-manufacturing sector, domestic healthcare demand, pharmaceutical import substitution, and the operating economics of medicine producers outside Tehran. It can support analysis of raw-material procurement, distributor receivables, product registration, pricing policy, and resilience during medicine shortages. Due diligence should review updated financial statements, product mix, API sourcing, GMP compliance, export channels, ownership, working capital, and exposure to currency or reimbursement delays.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 54
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 31
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 3
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 26
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 389
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 507
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 580
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 208
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026"
    }
}